Notably, numerous preclinical studies have confirmed the pharmacological blockade of STAT3 as a promising strategy for CRC therapy, supporting the role of STAT3 as a potential target for developing novel CRC therapeutics [21,22,23,24]. Here, STAT3 is linked to colorectal carcinoma.